Y-Intercept (HK)’s Takeda Pharmaceutical TAK Stock Holding History

Y-Intercept (HK)’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,973	Closed	-$265K	–	2036
2025 Q4	$265K	Buy	+16,973	New	+$243K	0.01%	1388
2023 Q2	–	Sell	-46,294	Closed	-$763K	–	1709
2023 Q1	$763K	Buy	46,294 +14,775	+47%	+$235K	0.09%	349
2022 Q4	$492K	Buy	+31,519	New	+$440K	0.07%	440
2022 Q1	–	Sell	-19,919	Closed	-$271K	–	944
2021 Q4	$271K	Buy	+19,919	New	+$279K	0.06%	426
2021 Q2	–	Sell	-34,683	Closed	-$636K	–	888
2021 Q1	$636K	Buy	+34,683	New	+$624K	0.17%	190

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Y-Intercept (HK)'s TAK Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 16,973 shares — an estimated $265K sold.

Y-Intercept (HK) first reported a position in TAK in Q1 2021 and held it in 5 quarters. The position peaked at $763K in Q1 2023. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Y-Intercept (HK) reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 16,973 Takeda Pharmaceutical shares in Q1 2026, an estimated $265K.
Y-Intercept (HK) first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 5 quarters.
Y-Intercept (HK)'s Takeda Pharmaceutical position peaked at $763K in Q1 2023.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.